The Watchman device is designed to be permanent. Once implanted, it does not wear out, expire, or require routine replacement. Within a few months of the procedure, your own heart tissue grows over the device, essentially absorbing it into the wall of your heart. At that point, the device becomes a permanent part of your anatomy.
Why the Device Is Permanent
The Watchman is a small, parachute-shaped implant made of a nickel-titanium frame covered in fabric. It’s placed inside the left atrial appendage, a small pouch in the heart where blood clots tend to form in people with atrial fibrillation. The goal is to seal off that pouch so clots can’t escape and cause a stroke.
After implantation, a natural process called endothelialization begins. Your heart tissue gradually grows over the surface of the device, covering it completely. In animal studies, this process reaches completion within about three months. In clinical practice, doctors expect substantial tissue coverage within 45 days, which is why a follow-up imaging scan is scheduled at that point. Once the device is fully covered by tissue, it’s effectively sealed into the heart wall permanently. There’s no moving part to wear down, no battery to deplete, and no material that degrades over time.
What Follow-Up Data Shows
Clinical studies have tracked patients with the Watchman for up to five years without reporting structural failures like frame fractures, material breakdown, or device migration requiring replacement. At the five-year mark, patients with the Watchman had a 9% lower relative risk of ischemic stroke compared to those taking warfarin, and a 28% lower relative risk of death from any cause. These numbers suggest the device continues working well years after implantation, not just in the months immediately following the procedure.
Potential Issues That Can Develop
While the device itself doesn’t degrade, it’s not entirely a set-and-forget situation. Two issues can affect how well it performs over time: leaks around the device and blood clots forming on its surface.
Leaks Around the Device
A large registry of over 51,000 patients found that about 73% had a complete seal with no leak at all. Roughly 26% had small leaks (5 millimeters or less), and less than 1% had large leaks. Small leaks were associated with a slightly higher risk of stroke and bleeding events, though the increase was modest. Interestingly, large leaks did not show a significant increase in adverse events, likely because those patients were kept on blood thinners as a precaution.
The newer Watchman FLX model was specifically redesigned to reduce leaks. It has a more conformable shape that molds to different appendage anatomies, resulting in better seal rates than the original Watchman 2.5 device.
Blood Clots on the Device Surface
Before the tissue fully covers the device, there’s a window where blood clots can form on its exposed surface. One study found device-related clots in about 6.4% of patients, typically appearing within the first few months. This is the primary reason you stay on blood-thinning medication during the initial recovery period. Once tissue growth covers the device completely, the risk drops significantly.
The Medication Timeline After Implantation
The whole point of getting the Watchman is to eventually stop taking blood thinners. That transition happens in stages over the first six months or so. In the original clinical trials, patients took warfarin plus low-dose aspirin for the first 45 days. After a successful imaging check at that point, they switched to two antiplatelet medications (aspirin and clopidogrel) for up to six months, then continued on aspirin alone indefinitely.
With the newer Watchman FLX, the initial 45-day protocol typically uses a direct oral anticoagulant (like apixaban or rivaroxaban) alongside low-dose aspirin instead of warfarin. The principle is the same: protect against clots during the healing window, then step down to simpler medication once imaging confirms the device is properly sealed and clot-free.
What the 45-Day Check Involves
At roughly 45 days after the procedure, you’ll have an imaging study to verify two things: the device is seated properly with minimal or no leak, and no blood clot has formed on its surface. This is most commonly done with a transesophageal echocardiogram, an ultrasound taken through the esophagus to get a close-up view of the heart. CT imaging is considered a reasonable alternative. If everything looks good, you transition off blood thinners according to the standard schedule. Beyond this check, routine imaging surveillance is not typically required unless new symptoms develop.
Original vs. Newer Watchman Models
The Watchman FLX, the second-generation device, introduced several design improvements that affect long-term performance. Its closed-end design allows for gentler delivery, which significantly reduces the risk of puncturing the heart wall during the procedure. Its more flexible frame conforms better to the appendage opening, leading to fewer and smaller leaks compared to the original device. In the original Watchman 2.5, about 73% of patients had a complete seal. The FLX consistently achieves higher complete-seal rates. These improvements don’t change the fundamental answer about longevity (both versions are permanent), but they do mean the newer device tends to perform better from the start.